At the AHN Amyloidosis Program, a team of doctors from various specialties collaborate to offer individualized treatment plans. These patient-centered therapies slow down the disease to help you feel better, for longer.
These symptoms are nonspecific and often associated with other conditions. However, such symptoms often determine the need for further testing to screen for amyloidosis.
In order to confirm an amyloidosis diagnosis and identify the specific subtype, AHN offers:
Treatment depends entirely on the subtype of amyloidosis and the organs that have been affected. Currently available treatments focus on stopping production of the defective proteins, removing deposits that have already accumulated, and helping the organs become more functional.
Light chain amyloidosis happens when too many antibody fragments called “light chains” are overproduced by the bone marrow. This process is cancer-like, so we work closely with hematologist-oncologists. As a team, we use chemotherapy to destroy those light-chain producing “factories.” Sometimes, a bone marrow transplant may be considered.
Transthyretin amyloidosis occurs when a defective transporter protein called transthyretin (TTR) is produced by the liver. These proteins can be abnormal due to either a mutation in the genetic code that is present at birth or, more commonly, as a consequence of aging. Some new medicines prevent defective TTR proteins from being produced by the liver, while others prevent abnormal proteins from being deposited in various organs.
For individuals with transthyretin amyloidosis (ATTR), genetic testing and counseling can help families confirm a diagnosis, guide treatment decisions, and plan for the future. Just having the mutation doesn’t mean someone will develop the disease, but it does mean that active monitoring is required and that the risk factor may be passed along to the next generation.